Biocross is a biotechnology company that seeks to improve
the life expectancy and quality of life of individuals with neurodegenerative diseases
through the design of innovative diagnostic systems.
This is achieved through the development of reliable
and non-invasive diagnostic tools that can be used
at any stage of the disease.
Biocross provides diagnostic solutions that can be used during the asymptomatic phase of the disease and enable early detection of individuals with increased risk of developing dementia.
Biocross has designed its products with a commitment to providing diagnostic tests of higher sensitivity and specificity than any currently available systems.
All of our diagnostic tests are based on the analysis of blood samples, and are applicable in hospital settings, thus ensuring patient safety and comfort.
To provide neurologists with an integrated diagnostic solution that can be applied to any stage of the disease, including the earliest, asymptomatic phase.
- Reduced cost of AD risk-assessment and diagnosis.
- More widespread testing thanks to simpler, more readily available diagnostic methods.
- Improved diagnosis, through earlier detection and differentiation of distinct dementia types.
- Simplified diagnosis through leveraging of existing laboratory equipment.
- Improved patient experience and safety.
The ApoE4 blood marker assay is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis.
The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. The input of these measurements into an algorithm provides an accurate diagnosis and classifies the patient as either Alzheimer´s disease or frontotemporal dementia.
The Degenerative dementia test is based on the detection and quantification of up to 7 blood biomarkers that are specifically altered in patients affected by neurodegeneration due to FTD or AD. The DD test is conceived as a “screening” tool for use in clinical practice.
By Labmedica International staff writers Posted on 24 Jul 2017 A clinical diagnostic kit that measures the concentration of the Alzheimer's disease blood biomarker APOEepsilon4 was unveiled at the Alzheimer’s Association Conference held in London, United Kingdom, from...read more
La compañía biotecnológica Biocross presentará un innovador test para la determinación en 10 minutos del riesgo de desarrollar la enfermedad de Alzheimer
El Alzheimer, enfermedad neurodegenerativa, afecta actualmente a 37 millones de personas en todo el mundo y se espera que la cifra aumente a 131 millones en 2050 El test de riesgo ApoE4 Blood Marker Assay es una prueba en sangre, coste-efectiva y contrastada que...read more
ApoE4 blood marker assay. A new non-genetic method to evaluate Alzheimer´s disease risk using clinical chemistry platforms
Biocross was pleased to present at the 9th Clinical trials on Alzheimer’s Disease (CTAD) meeting, to be held in San Diego, the ApoE4 blood marker assay, a new non-genetic method to evaluate Alzheimer’s disease risk. To date only the presence of one or two APOE ε4...read more
If you have any questions or comments, we will be pleased to attend you
If you have any questions or comments,
we will be pleased to attend you